Italia markets closed
FTSE MIB
34.249,77 +310,02 (+0,91%) Dow Jones
38.239,66 +153,86 (+0,40%) Nasdaq
15.927,90 +316,14 (+2,03%) Nikkei 225
37.934,76 +306,28 (+0,81%) Petrolio
83,66 +0,09 (+0,11%) Bitcoin EUR
59.423,37 +548,17 (+0,93%)
Neurocrine Biosciences, Inc. (0K6R.L)
LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
Alla chiusura: 07:14PM BST
| Chiusura precedente | 136,93 |
| Aperto | 138,41 |
| Denaro | 0,00 x 0 |
| Lettera | 0,00 x 0 |
| Min-Max giorno | 135,96 - 138,61 |
| Intervallo di 52 settimane | 89,66 - 143,27 |
| Volume | |
| Media Volume | 1.189 |
| Capitalizzazione | 135,435M |
| Beta (5 anni mensile) | 0,28 |
| Rapporto PE (ttm) | 1,89 |
| EPS (ttm) | 0,73 |
| Prossima data utili | 01 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireSosei Heptares’ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric conditionsNBI-1117570 is the second compound to advance into clinical development from a portfolio of selective muscarinic receptor agonists licensed by Sosei Heptares to Neurocrine following NBI-1117568, an oral, selective muscarinic M4 receptor agonist, which is in Phase 2 clinical trials as an investigational treat
© 2024 Yahoo. Tutti i diritti riservati.